ArticleCancer biology & therapy2014

Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy.

Shandiz Shahbazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.